#None #NASDAQ #IM Cannabis #CSE

IM Cannabis Corp. Plans to Voluntarily Withdraw from the CSE

IM Cannabis Corp., known for its medical cannabis offerings, has announced its intention to voluntarily delist its common shares from the Canadian Securities Exchange (CSE). This strategic move reflects the company’s ongoing efforts to streamline its operations and focus on its primary listing on the NASDAQ where it trades under the symbol "IMCC."

Rationale Behind the Decision

The decision to delist from the CSE comes as IM Cannabis aims to eliminate unnecessary costs associated with maintaining dual listings. The company has noted that the trading volume on the CSE no longer justifies the administrative expenses and regulatory burdens of such a listing. By concentrating its efforts on the NASDAQ, IM Cannabis believes it can create a more central marketplace for its shares, enhancing liquidity and shareholder value in the long run.

CEO Oren Shuster emphasized the importance of this move: “Delisting from the CSE will allow us to optimize our operations and reduce unnecessary complexities, ultimately benefiting our shareholders.” The company is currently seeking approval from the CSE, anticipating that its final trading day will be June 2, 2025.

Corporate Overview

Established as an international player in the cannabis sector, IM Cannabis has made strides in providing high-quality medical cannabis products. It primarily serves patients in Israel and Germany, which are recognized as some of the world’s largest medical cannabis markets. The company operates through a data-driven ecosystem that enables it to tailor its offerings effectively.

In Israel, subsidiaries like Focus Medical Herbs Ltd. manage the import and distribution of cannabis products to medical users. This organizational structure is designed to leverage years of data and patient insights to ensure that all products meet high standards of quality and safety.

In Germany, IM Cannabis collaborates with Adjupharm GmbH to supply pharmacies, reinforcing the company’s robust operational framework across borders. This dual-market approach underscores IM Cannabis’s commitment to responsible operations and excellence in product delivery.

Future Outlook

As IM Cannabis prepares for its transition away from the CSE, it remains dedicated to its vision of becoming a dominant player in the global cannabis industry. The company is poised to capitalize on potential transactions that may arise, facilitating growth and expansion in accordance with its business strategy. Shuster notes, “We're excited about the prospects ahead and are committed to driving value for our stakeholders.”

While the upcoming delisting may present challenges, IM Cannabis is focused on fostering long-term growth through strategic decisions and operational improvements. Shareholders can continue to trade their holdings on the NASDAQ under the IMCC symbol, providing them with continued access to the company’s updates and developments.